Drug Shortage Report for HYDROMORPHONE HYDROCHLORIDE INJECTION, USP

Last updated on 2022-10-02 History
Report ID 168499
Drug Identification Number 02491699
Brand name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Common or Proper name HYDROMORPHONE HYDROCHLORIDE INJECTION, USP
Company Name FRESENIUS KABI CANADA LTD
Market Status MARKETED
Active Ingredient(s) HYDROMORPHONE HYDROCHLORIDE
Strength(s) 2MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR
Packaging size 1mL
ATC code N02AA
ATC description OPIOIDS
Reason for shortage Demand increase for the drug.
Anticipated start date 2022-08-08
Actual start date 2022-08-08
Estimated end date Unknown
Actual end date 2022-09-30
Shortage status Resolved
Updated date 2022-10-02
Company comments This product will be placed on allocation. Contract customers will be allocated 100% of historical monthly demand.
Health Canada comments
Tier 3 Status No
Contact Address 165 GALAXY BLVD, SUITE 100
TORONTO, ONTARIO
CANADA M9W 0C8
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v4 2022-10-02 French Compare
v3 2022-10-02 English Compare
v2 2022-09-01 French Compare
v1 2022-09-01 English Compare

Showing 1 to 4 of 4